Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lung Cancer News

NICE Approves Lung-Cancer Drug Provided Manufacturer Roche Offers Discounted Price For NHS, UK

Main Category: Lung Cancer
Also Included In: Cancer / Oncology
Article Date: 28 Nov 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

The National Institute for Health and Clinical Excellence (NICE) has recommended erlotinib, an epidermal growth factor receptor inhibitor, as an alternative to docetaxel as a second-line treatment option for patients with non-small-cell lung cancer (NSCLC) provided the manufacturer (Roche) supplies erlotinib at a discounted and equivalent price to docetaxel. A Special Report in The Lancet Oncology published early Online reports on the evidence considered during this final approval process.

NICE had previously ruled against recommending the drug and after considering some quality of life issues such as the oral administration of erlotinib and the reduced risk of toxicities such as febrile neutropenia, the NICE Committee concluded that these additional benefits were not sufficient to consider erlotinib cost-effective compared with docetaxel. However, after Roche proposed a scheme to equalise costs between the two treatments, the Committee recommended approval for patients as an alternative second-line treatment: "The recommendation was made on the condition that the manufacturer provides erlotinib at an overall treatment cost (including administration, adverse events, and monitoring costs) equal to that of docetaxel", state the authors of the Special Report. This is the latest example of NICE and manufacturers collaborating to reduce drug costs within the NHS.

For full Special Report please see: http://press.thelancet.com/TLOnice.pdf

Tony Kirby
Press Officer
The Lancet
32 Jamestown Road
Camden
London
NW1 7BY
http://www.TheLancet.com




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
START Trial Will Show Whether Therapeutic Vaccine Stimuvax Has Potential To Extend Lung Cancer Survival Beyond Five Years
01 Jun 2009
Of all cancers, non-small cell lung cancer (NSCLC) represents one of the greatest unmet needs for an effective and life-prolonging treatment. The condition, which accounts for 85 per cent of all lung cancers - roughly 1...


Advanced Lung Cancer image Advanced Lung Cancer

Doctors are finding that some patients with advanced non-small cell lung cancer may benefit from radiation, chemotherapy and/or newer treatment combinations...

New Lung Cancer Therapies image New Lung Cancer Therapies

New therapies are improving the survival rates for patients with lung cancer. How do these treatments work...

View more videos...